Author:
Hussain Basha Syed,Prasad R Nalini
Abstract
Abstract
Background
Neuraminidase (NA) is a prominent surface antigen of Influenza viruses, which helps in release of viruses from the host cells after replication. Anti influenza drugs such as Oseltamivir target a highly conserved active site of NA, which comprises of 8 functional residues (R118, D151, R152, R224, E276, R292, R371 and Y406) to restrict viral release from host cells, thus inhibiting its ability to cleave sialic acid residues on the cell membrane. Reports on the emergence of Oseltamivir resistant strains of H1N1 Influenza virus necessitated a search for alternative drug candidates. Pleconaril is a novel antiviral drug being developed by Schering-Plough to treat Picornaviridae infections, and is in its late clinical trials stage. Since, Pleconaril was designed to bind the highly conserved hydrophobic binding site on VP1 protein of Picorna viruses, the ability of Pleconaril and its novel substituted derivatives to bind highly conserved hydrophobic active site of H1N1 Neuraminidase, targeting which oseltamivir has been designed was investigated.
Result
310 novel substituted variants of Pleconaril were designed using Chemsketch software and docked into the highly conserved active site of NA using arguslab software. 198 out of 310 Pleconaril variants analyzed for docking with NA active site were proven effective, based on their free binding energy.
Conclusion
Pleconaril variants with F, Cl, Br, CH3, OH and aromatic ring substitutions were shown to be effective alternatives to Oseltamivir as anti influenza drugs.
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference25 articles.
1. Noble D, Colatsky TJ: A return to rational drug discovery: computer-based models of cells, organs and systems in drug target identification. Emerging therapeutic targets. 2000, 4: 39-49. 10.1517/14728222.4.1.39.
2. Ekins S, Mestres J, Testa B: In-silico pharmacology for drug discovery: Applications to targets and beyond. Br J Pharmacol. 2007, 152: 21-37. 10.1038/sj.bjp.0707306.
3. John Cartar B, Venetia Saunders A: Virology-principles and applications. 2007, India: John Wiley and sons limited publications, 317-322. First
4. Von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, et al: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993, 363: 418-423. 10.1038/363418a0.
5. Aoki FY, Boivin G, Roberts NA: Influenza virus susceptibility and resistance to Oseltamivir. Anti viral Therapy. 2007, 12: 603-616.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献